IJR News

OpenAI Cancels Astra Release Over Safety Concerns — Sep 28, 2026OpenAI canceled GPT-6.1 Astra’s October release after Saachi Jain said it "didn’t quite meet the bar" on scope, authorization and telling users what work it did.

0

Elena Vasquez Holding back on scope makes sense if the model might overstep without proper checks in place.

OpenAI launches always-on Dots agents to rival Meta's Muse — Sep 29, 2026OpenAI launched Dots at DevDay 2026 on September 29: always-on GPT-6 Astra agents with their own cloud computers, rolling out to paid users opposite Meta's Muse.

+2

Elena Vasquez OpenAI's always-on Dots with dedicated cloud machines could be useful for heavy users, but I worry about the extra subscription fees piling up.

Vertex Lab Combines V2Fun AI With GPT-6 Astra for Editable 3D Assets — Sep 11, 2026Vertex Lab showcased a component-based workflow that merges its V2Fun 3D generation with GPT-6 Astra’s planning and coding to turn reference images into assembled, editable 3D assets, preserving major components for later editing. The demos, including an excavator and armored character, use Three.js to assemble parts and add detailed features, highlighting how procedural and hybrid approaches can shape final models.

+2

Elena Vasquez The excavator demo shows real promise for keeping parts separate instead of baking everything into one mesh.

OpenAI launches ChatGPT for Financial Services aimed at Wall Street tasks — Sep 10, 2026OpenAI has rolled out ChatGPT for Financial Services, a tailored enterprise product powered by GPT-6 Astra that combines its AI with data from vendors like LSEG, PitchBook, and Daloopa, developed with Morgan Stanley and Evercore as design partners to aid analysts, researchers, and presentation work for Wall Street. The offering emphasizes governance and compliance—role-based access, encryption, and exportable logs—while enabling firms to integrate their existing data subscriptions and extend coverage across multiple sources to improve retrieval, citation, and client-material generation.

+1

Priya Raman This integration with LSEG and PitchBook data could finally cut down the time analysts spend hunting across separate platforms.

Myriad Genetics, SOPHiA GENETICS and AstraZeneca advance prostate cancer biomarkerHealth — 1dMyriad Genetics, SOPHiA GENETICS and AstraZeneca are collaborating to advance Myriad’s prostate cancer genomic instability score, designed to identify tumors with features associated with homologous recombination deficiency. Myriad’s MyChoice CDx test will generate the score, while SOPHiA plans to develop a decentralized companion diagnostic; the technology is being studied for clinical trials and is not yet an approved prostate cancer test.

0

Most Influential Women in World HistoryYourlist — RankingFrom ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.

AstraZeneca Completes $2B Summit Cancer Drug InvestmentBusiness — Oct 2, 2026AstraZeneca has completed its $2 billion equity investment in Summit Therapeutics to accelerate development of ivonescimab, an investigational PD-1/VEGF cancer antibody. The companies are also advancing clinical collaborations that pair ivonescimab with antibody-drug conjugates across several cancers, including lung and breast cancer.

0

AstraZeneca invests $2 billion in Summit cancer drug partnership — Sep 28, 2026AstraZeneca will invest $2 billion in Summit Therapeutics convertible preferred shares, with Summit stock up more than 17% after-hours ahead of a November 14 FDA decision on ivonescimab.

+1

Marcus Bell This deal could help bring the cancer drug to market faster if the November decision goes well.

AstraZeneca Breast Cancer Trial Misses Key Goal — Sep 11, 2026AstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial when added to standard therapy, despite an earlier ESR1 mutation–targeted approval and after-hours stock weakness. The broader trial that reached more patients failed, while a separate study in ESR1-mutant patients showed a meaningful benefit, underscoring a split outcome for the drug’s potential.

+3

Marcus Bell It's frustrating the overall trial missed but good the ESR1 group still saw real benefit from the drug.

Imfinzi Bladder Combo Wins FDA Priority Review — Sep 25, 2026Up to half of muscle-invasive bladder cancer patients cannot take standard chemo. FDA gave Priority Review to AstraZeneca's IMFINZI-enfortumab combo for them; decision due Q4 2026.

+2

Maya Lindstrom Priority review makes sense here but the 2026 decision date still leaves people waiting too long for access.

Legend Biotech names Novartis executive Ingrid Zhang CEO — Sep 15, 2026Legend Biotech appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026, with interim CEO Alan Bash becoming President of CARVYKTI. Zhang, a former Novartis executive and China head, brings broad global leadership experience from AstraZeneca, Pfizer, and McKinsey as the board positions Legend for its next growth phase.

+2

Tom Gallagher Hiring someone with McKinsey and AstraZeneca experience signals the board wants tighter global operations going forward.

OpenAI Unveils GPT-6 Astra Amid Safety ScrutinyTech — Sep 2, 2026OpenAI is delaying and restricting access to its new Astra model, which has reached a Critical cybersecurity capability rating and can autonomously identify and exploit security flaws, prompting heightened safeguards, monitoring, and a staged rollout to a small group of testers and trusted partners. The company says Astra will be released soon with defensive uses prioritized and ongoing safety testing, after recent incidents and intensified red-teaming prompted new security measures.

0

Quentin Tarantino vs Martin ScorseseYourlist — VS BattleThe video store savant versus the film-school don — two visions of American violence, guilt, and cool.

OpenAI Claims AI Solved Navier-Stokes Millennium Problem Amid Credit AllegationsTech — Sep 8, 2026OpenAI has announced breakthroughs claiming solutions to Millennium Prize Problems, including a Navier–Stokes related result produced by AI, though scholars have questioned attribution and raised concerns about credit and originality. The debate expanded as OpenAI’s Astra model allegedly solved 10 longstanding problems at minimal compute cost, attracting criticism over undisclosed prior work and potential research misconduct.

0

Three Men Killed in Wheathampstead Hertfordshire Two-Vehicle Crash — Jul 23, 2026A two-vehicle crash on Cory Wright Way in Wheathampstead involving a silver Vauxhall Astra and a grey BMW 840i killed three men in their 30s to 50s and left the BMW driver seriously injured, with conditions of the victims and ongoing investigations being reported by multiple outlets; police have appealed for witnesses and dash-cam footage as road closures were lifted.

0

Expert WHO Committee To Review AstraZeneca Vaccine After Worrying Side Effects AppearReporting — Mar 14, 2021Even amid concerns that have led an increasing number of countries to stop distributing the COVID-19 vaccine produced by AstraZenecaa, the World Health Organization is urging its continued use. The WHO’s global advisory…

0

AstraZeneca India CFO Bhavana Agrawal to resignBusiness — Jul 21, 2026AstraZeneca Pharma India said CFO and Whole-Time Director Bhavana Agrawal will resign to take a regional role within the AstraZeneca Group, effective August 31, 2026, with a multi‑week handover and a search for a successor. Regulatory filings confirm the move as part of global realignment, while the company notes strong FY2025-26 growth, including about 33% higher revenue and solid PAT, underscoring ongoing operational resilience.

0

The grammar gatekeeper testQuizie — QuizTwelve spelling and grammar traps that catch almost everyone. Pass, and the AI knights you. Fail, and it's gentle about it. Mostly.

AstraZeneca Ends Phase III Lung Cancer Trial — Aug 17, 2026AstraZeneca reports a setback as its Phase III trial of volrustomig plus chemotherapy in PD-L1 negative metastatic non-small cell lung cancer is halted after an independent data review found it unlikely to meet primary endpoints, while another late-stage study in cervical cancer and other indications continues. In a positive contrast, AZN and partners SAFFRON showed that Tagrisso combined with Orpathys significantly improved progression-free and overall survival, underscoring a mixed near-term outlook but ongoing strength in its immuno-oncology pipeline.

0

AstraZeneca Posts Q2 Beat, Reaffirms 2026 Outlook — Jul 24, 2026AstraZeneca beat second-quarter profit expectations and reaffirmed its 2026 outlook despite concerns about future growth after a trial setback, as investors await further details on its earnings trajectory. Analysts are mixed but broadly positive, with several buy ratings and a focus on the upcoming Q2 results and oncology-driven revenue, amid a broader market backdrop of cautious trading ahead of earnings.

0

EU Approves Etcamah in First-Line ER+ Breast Cancer — Jul 23, 2026AstraZeneca’s Etcamah (camizestrant) won EU approval to be used with CDK4/6 inhibitors as a first-line treatment for ER-positive, HER2-negative advanced breast cancer in patients with ESR1 mutations, based on SERENA-6 trial results showing a 56% reduction in progression or death. The drug already has approvals in Japan, the UAE, and Saudi Arabia, with U.S. review ongoing and the EU decision highlighting its potential to expand AstraZeneca’s oncology footprint as it targets endocrine-resistant disease.

0

Coroner Rules Young Doctor Died from Blood Clot Due to COVID Vaccine – Wife Wants Death Certificate ChangedReporting — Apr 24, 2023A London Coroner’s Court has ruled that the blood clot that killed British psychologist Stephen Wright in January 2021 was linked to the AstraZeneca COVID-19 vaccine. The AstraZeneca vaccine is not approved for use in…

0

AstraZeneca Says US Data Load for US COVID-19 Vaccine Approval Very BigReporting — Apr 30, 2021AstraZeneca is working as fast as possible to compile data on its COVID-19 vaccine to apply for U.S. approval but the dataset is very big, executives said on Friday as the drugmaker faces delays to its submission…

0

US To Share Up to 60 Million AstraZeneca Vaccine Doses Globally: White HouseReporting — Apr 26, 2021The United States will start to share up to 60 million doses of AstraZeneca Plc’s coronavirus vaccine with other countries as soon as the next few weeks, the White House said on Monday. White House Press Secretary Jen…

0

AstraZeneca Shot Is Good If Safety Issues Can Be Overcome, Fauci SaysReporting — Apr 13, 2021U.S. infectious disease official Anthony Fauci said AstraZeneca’s COVID-19 vaccine had good efficacy, but safety concerns needed to be straightened out and it might not be needed for Americans because of supplies of…

0

Investigation Finds ‘Clear’ Link Between AstraZeneca COVID-19 Vaccine and Blood Clots in BrainReporting — Apr 6, 2021A link between AstraZeneca’s COVID-19 vaccine and rare blood clots in the brain has been discovered, but officials have yet to identify a possible cause, according to a senior European Medicines Agency official. “In my…

0

AstraZeneca Says COVID-19 Vaccine 76 Percent Effective in New Analysis, To Seek US ApprovalReporting — Mar 25, 2021AstraZeneca’s said its COVID-19 vaccine was 76% effective in a new analysis of its U.S. trial – only a tad lower than the level in an earlier report this week criticised for using outdated data. Interim data published…

0